IN THIS EPISODE - What a peptide actually is, and why your GLP-1 is NOT the same thing as BPC-157 or TB-500 - The seven peptides the FDA is reviewing: BPC-157, KPV, TB-500 (the "Wolverine complex"), MOTS-c, DSIP, Semax, and Epitalon - The "funding gap" why peptides that can't be patented never get human clinical trials - Six things the FDA worries about in an unlabeled vial, from identity and purity to the cancer/angiogenesis risk - The two questions that tell you if a peptide provider is legitimate (503A/B pharmacies and third-party certificates of analysis) ABOUT THE GUEST Tanna Donalson is a Physician Assistant and Owner of Redbud Medical in Denver Colorado
Although there is no absolute contraindication to using both medications together, their opposing metabolic effectsparticularly on appetite, weight, and blood glucoserequire careful monitoring and individualised management
Henriksen MM, Andersen HU, Thorsteinsson B, Pedersen-Bjergaard U (2018) Hypoglycemic exposure and risk of asymptomatic hypoglycemia in type 1 diabetes assessed by continuous glucose monitoring
Dng vin ngm di li l dng dng duy nht c nghin cu lm sng cho thy hiu qu trng da vi ngi chu ng ti Tp ch khoa hc th gii
Increased intake of vegetable oil rich in n-6 PUFA enhances allergic symptoms and prevents oral tolerance induction in whey-allergic mice
